Intravenous Immunoglobulin (IVIG) in Pediatrics - Overview

1. Kawasaki disease - the classic pediatric indication; single high-dose IVIG + aspirin to prevent coronary artery aneurysms, IVIG-resistance and second-line therapy (infliximab, steroids)
2. Immune thrombocytopenia (ITP) - IVIG for rapid platelet rise in bleeding/severe thrombocytopenia, high-dose vs low-dose regimens
3. Primary immunodeficiency diseases - replacement therapy in conditions like X-linked agammaglobulinemia, CVID, SCID
4. Neuroimmunologic conditions - Guillain-Barre syndrome, CIDP, pediatric dermatomyositis, autoimmune encephalitis
5. MIS-C (multisystem inflammatory syndrome in children) - IVIG use post-COVID, often combined with steroids
6. Mechanism of action, dosing, and administration - how IVIG works immunologically, standard dosing regimens, infusion protocols
7. Adverse effects and safety - infusion reactions, aseptic meningitis, thrombosis, hemolysis, IgA deficiency/anaphylaxis risk

Intravenous Immunoglobulin (IVIG) in Pediatrics - Overview

1. Kawasaki disease - the classic pediatric indication; single high-dose IVIG + aspirin to prevent coronary artery aneurysms, IVIG-resistance and second-line therapy (infliximab, steroids)
2. Immune thrombocytopenia (ITP) - IVIG for rapid platelet rise in bleeding/severe thrombocytopenia, high-dose vs low-dose regimens
3. Primary immunodeficiency diseases - replacement therapy in conditions like X-linked agammaglobulinemia, CVID, SCID
4. Neuroimmunologic conditions - Guillain-Barre syndrome, CIDP, pediatric dermatomyositis, autoimmune encephalitis
5. MIS-C (multisystem inflammatory syndrome in children) - IVIG use post-COVID, often combined with steroids
6. Mechanism of action, dosing, and administration - how IVIG works immunologically, standard dosing regimens, infusion protocols
7. Adverse effects and safety - infusion reactions, aseptic meningitis, thrombosis, hemolysis, IgA deficiency/anaphylaxis risk

What IVIG Is and How It Works

• Replacement therapy - restoring IgG levels in antibody-deficient patients
• Immunomodulation - high-dose IVIG exerts anti-inflammatory/immunomodulatory effects via multiple proposed mechanisms: Fc receptor blockade on macrophages, saturation of the neonatal Fc receptor (FcRn) accelerating clearance of pathogenic autoantibodies, anti-idiotype antibody neutralization, complement scavenging, and modulation of cytokine networks and Fas-mediated apoptosis.

Major Pediatric Indications

Adverse Effects and Safety

• Infusion reactions: headache, flushing, fever, myalgia - most common, often rate-related
• Aseptic meningitis: can occur 24-72 hours post-infusion, more common with high-dose regimens
• Thrombosis: due to increased serum viscosity, more relevant in older/immobile patients but still a consideration
• Renal impairment: historically linked to sucrose-containing formulations, now less common with modern products
• Hemolysis: from anti-A/anti-B isoagglutinins in the product
• Anaphylaxis: rare, but a concern in patients with severe IgA deficiency and anti-IgA antibodies - IgA-depleted products are preferred in this group

Intravenous Immunoglobulin (IVIG) in Children - Detailed Review

1. Synthesis / Manufacture

• Source: Pooled plasma from thousands of healthy screened donors (typically 1,000-60,000 donors per production lot), giving the final product a broad, representative spectrum of antibodies reflecting the donor population's infectious and immunization history - Red Book 2021.
• Purification process: Classically produced by cold ethanol fractionation (the Cohn fractionation method), which separates plasma proteins based on differential solubility in ethanol at controlled temperatures and pH. This yields "Cohn fraction II," which is at least 90% IgG with only trace IgA and IgM - Red Book 2021. Modern manufacturing also uses ion-exchange chromatography and other purification steps to improve purity and reduce IgA content.
• Viral inactivation: Products are treated with solvent/detergent methods (and other steps such as pasteurization or nanofiltration) to inactivate lipid-enveloped viruses, making transmission of HIV, hepatitis B/C, and similar pathogens essentially unrecorded from modern licensed IVIG.
• Formulation: Final concentrated protein solutions (roughly 5-16.5% depending on product), some stabilized with sucrose, glycine, glucose, or proline - the excipient matters clinically (sucrose-containing formulations carry higher renal risk, discussed below).
• Distinction from IGIM: Intramuscular immunoglobulin (IGIM) is made similarly but is licensed only for IM use and is not the product used for the immunomodulatory indications discussed here.

2. Mechanism of Action

• Fc receptor blockade on macrophages/monocytes, reducing Fc-mediated phagocytosis of antibody-coated cells (e.g., platelets in ITP)
• Anti-idiotype antibody interactions - neutralizing pathogenic autoantibodies
• Interference with complement activation and scavenging of complement components before they cause tissue damage
• Cytokine and costimulatory molecule modulation, dampening the inflammatory cascade
• Induction of apoptosis in target cells through Fc receptor engagement (Firestein & Kelley's Textbook of Rheumatology, p. 7899)
• Sialic acid-dependent immune modulation - a more recently described mechanism where sialylated Fc glycans on IVIG's IgG molecules engage specific receptors to dampen immune activity (Roitt's Essential Immunology, p. 2689)
• Saturation of the neonatal Fc receptor (FcRn), which recycles IgG and, when saturated by the IVIG bolus, accelerates clearance of pathogenic autoantibodies

3. Uses in Children

• Primary immunodeficiencies (X-linked agammaglobulinemia, common variable immunodeficiency, severe combined immunodeficiency, DiGeorge syndrome with humoral component)
• HIV infection with antibody deficiency (IgG <400 mg/dL with failure to form antibodies to common antigens)
• Severe hypogammaglobulinemia (IgG <100 mg/dL) - the Harriet Lane Handbook notes these children may need a higher total loading dose split into two doses days apart, then standard maintenance every 3-4 weeks
• Prior to measles prophylaxis in susceptible immunocompromised children

• Kawasaki disease - single 2 g/kg infusion with high-dose aspirin within the first 10 days; reduces coronary aneurysm risk from ~25% to <5%. A 2023 Cochrane review (PMID 36695415) confirms this remains the evidence-based standard, with ongoing study of optimal dosing regimens and management of IVIG-resistant cases (second dose, corticosteroids, or infliximab)
• Immune thrombocytopenia (ITP) - for rapid platelet elevation in bleeding or severe thrombocytopenia; a 2024 meta-analysis (PMID 38515126) suggests low-dose regimens may work comparably to high-dose in newly diagnosed pediatric ITP
• Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP)
• Streptococcal/staphylococcal toxic shock syndrome - neutralizes circulating superantigens
• Pediatric dermatomyositis and other autoimmune/inflammatory dermatoses (epidermolysis bullosa acquisita, autoimmune blistering diseases)
• MIS-C (multisystem inflammatory syndrome in children), usually combined with corticosteroids
• Investigational/less certain: acute viral myocarditis in children - a 2025 systematic review of RCTs (PMID 39754433) found the evidence still limited and not conclusively supportive, so this should be considered non-standard rather than routine

4. Adverse Effects in Children

• Fever, headache, myalgia, arthralgia, flushing - often rate-dependent and reduced by slowing the infusion

• Aseptic meningitis - fever, headache, photophobia, neutrophilic pleocytosis or eosinophilia in CSF; a recognized drug-induced cause of aseptic meningitis alongside NSAIDs (Fitzpatrick's Dermatology, p. 1345-1346; also discussed in Harrison's and Adams and Victor's Principles of Neurology)
• Anaphylaxis - rare, but a specific concern in children with primary IgA deficiency who have developed anti-IgA antibodies; checking serum IgA before first infusion in high-risk patients is recommended, and IgA-depleted products should be used if IgA deficiency is confirmed
• Renal impairment/nephropathy - historically associated with sucrose-containing IVIG formulations, now less common with modern sucrose-free products
• Thromboembolic complications - related to increased serum viscosity; more relevant with rapid infusion, dehydration, or in patients with vascular risk factors (less common in children than adults, but still reported)
• Hemolytic anemia - from anti-A/anti-B isoagglutinins present in pooled donor plasma
• A 2023 systematic review specifically on IVIG adverse reactions in neurological disorders (PMID 37015212) reinforces that most reactions are mild and infusion-related, with anaphylaxis and aseptic meningitis being the serious but uncommon events to monitor for.

Developmental Screening and Diagnostic Tools Used in India

A. Indigenous Indian Screening Tools

• Age range: 0-6 years (a validated Hindi version has also been studied specifically for 1-30 months)
• Components: 17 items covering 4 domains - gross motor, fine motor/adaptive, personal-social, and language
• Timing/administration: 5-15 minutes; directly administered through history-taking and examination by the provider
• Interpretation: Pass/fail scoring per item; developmental delay is flagged if the child fails ≥1 age-appropriate item
• Notes: Minimal training needed, so it's widely used as a community/office-based screening tool; sensitivity around 66.8%. Developed from Bayley Scales of Infant Development concepts, with Indian normative data.

• Age range: 0-30 months
• Components: 54 items assessing 2 domains - motor and mental development
• Timing/administration: 10-20 minutes; directly administered
• Interpretation: Developmental age is derived from the 50th and 97th percentile item-pass placements
• Notes: Derived from selected BSID items with Baroda (Indian) norms. Sensitivity 65-93%, specificity ~95%. Minimal training required - suitable for community health workers doing door-to-door surveys.

• Age range: 0-6 years
• Components: 66-item parent interview covering gross motor, vision & fine motor, hearing/language & concept development, and self-help & social skills
• Timing/administration: Minimal time, done as a parent interview; no formal training required
• Interpretation: Results plotted as centiles (3rd, 5th, 25th, 50th, 75th, 95th, 97th); significant delay defined as below the 3rd centile (~2 SD below mean)

• Age range: 6 months to 2 years (a more recently developed, narrower-age Indian screening tool, less widely used than the above three)

B. Indian Diagnostic (Gold-Standard) Tools

• Age range: Birth to 30 months (1-30 months)
• Components: Indian adaptation of the Bayley Scales of Infant Development, using indigenous test material; generates separate Mental Developmental Quotient (DQ) and Motor DQ
• Timing/administration: Requires a trained examiner and takes considerably longer than screening tools (directly administered, structured item sets); it is used for diagnostic confirmation, not quick office screening
• Notes: Remains the mainstay diagnostic/confirmatory tool in India and is used as the reference standard against which newer Indian screening tools are validated. A known limitation: DASII cutoff points for categorizing delay are inconsistently reported across studies, so interpretation varies by center.

• Age range: Birth to 15 years
• Components: Assesses social and adaptive functioning/social competency across multiple life domains
• Timing/administration: Culturally adapted for Indian use; usable even in non-verbal or motor-impaired children since it relies on caregiver report of functional behavior
• Notes: Easy and quick relative to full cognitive testing; commonly used alongside cognitive/motor tools to complete a functional diagnostic picture.

C. Internationally Developed Tools Used/Adapted in India

• Age range: 1-66 months, using 21 separate age-specific forms
• Components: 30 questions per form across 5 domains - gross motor, fine motor, communication, problem-solving, personal-social
• Timing/administration: 10-15 minutes; parent/caregiver-reported, can be self-completed or done with professional assistance
• Interpretation: Risk categorization into typical / needs monitoring / needs further assessment

• Age range: 16 days to 42 months
• Components: 5 domains - cognitive, language, motor, social-emotional, adaptive behavior
• Notes: The international gold standard from which DASII was derived; used in India mainly in research/tertiary diagnostic settings since it lacks Indian-specific norms.

• Used widely in Indian community-based surveys (roughly ages 2-9 years) as a very brief screen for major disabilities - vision, hearing, motor impairment, cognitive delay, and seizures - useful for large-scale epidemiological screening rather than individual diagnostic use.

D. Neurodevelopmental Disorder-Specific Tools (INCLEN Suite)

• Developed by a consortium of Indian and international neurodevelopmental experts specifically for Indian primary-care use
• Screens for 10 neurodevelopmental disorders: autism spectrum disorder, learning disorder, ADHD, vision impairment, hearing impairment, intellectual disability, speech and language disorder, epilepsy, cerebral palsy, and other neuromuscular disorders
• Positive screens are followed by disorder-specific INCLEN Diagnostic Tools (INDT) - e.g., INDT-ASD (autism), INDT-ID (intellectual disability), INDT-NMI (neuro-motor impairment), INDT-Epilepsy - each validated with Indian normative data for confirmatory diagnosis at primary-care level.

Quick Comparison Summary